/VINC
VINC Stock - Vincerx Pharma, Inc.
Healthcare|BiotechnologyNASDAQ
$0.01+0.00%
+$0.00 (+0.00%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.54
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+22976.9%upside
Target: $3.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VINC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$3.00
STOP LOSS$0.01
RISK/REWARD1:995.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.64
52W High$10.38
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-915,000 | $-939,000 | $-340,000 | $-172,996 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-31,463,000 | $-42,609,000 | $-68,722,000 | $-62,656,000 | $-10,714,000 |
| Net Income | $-30,074,000 | $-40,157,000 | $-65,367,000 | $-39,306,000 | $-16,620,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-5.75 | $-6.84 | $-10.86 | $-8.30 | $-11.67 |
Company Overview
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
VINCBeat Rate
50%
Last 16 quarters
Avg Surprise
+7.1%
EPS vs Estimate
Beats / Misses
8/6
2 met exactly
Latest EPS
$-0.91
Q2 2025
EPS Surprise History
Q3 23
+20.0%
$-10.40vs$-13.00
Q4 23
+6.1%
$-9.20vs$-9.80
Q1 24
+45.2%
$-4.60vs$-8.40
Q2 24
-30.8%
$-6.80vs$-5.20
Q3 24
+70.6%
$-1.00vs$-3.40
Q4 24
0.0%
$-3.40vs$-3.40
Q1 25
-23.5%
$-4.20vs$-3.40
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 10, 2025 | — | — | — | — |
Q3 2025 | Aug 28, 2025 | — | — | — | — |
Q2 2025 | May 15, 2025 | — | $-0.91 | — | — |
Q1 2025 | Mar 27, 2025 | $-3.40 | $-4.20 | -23.5% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-3.40 | $-3.40 | 0.0% | = MET |
Q3 2024 | Aug 8, 2024 | $-3.40 | $-1.00 | +70.6% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-5.20 | $-6.80 | -30.8% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-8.40 | $-4.60 | +45.2% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-9.80 | $-9.20 | +6.1% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-13.00 | $-10.40 | +20.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-13.80 | $-13.60 | +1.4% | ✓ BEAT |
Q1 2023 | Mar 28, 2023 | $-12.60 | $-13.00 | -3.2% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-16.00 | $-16.00 | 0.0% | = MET |
Q3 2022 | Aug 11, 2022 | $-18.40 | $-17.60 | +4.3% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.76 | $-0.79 | -3.9% | ✗ MISS |
Q1 2022 | Mar 29, 2022 | $-0.93 | $-0.31 | +66.7% | ✓ BEAT |
Q4 2021 | Nov 12, 2021 | $-0.85 | $-1.39 | -63.5% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.37 | $-0.12 | +67.6% | ✓ BEAT |
Q2 2021 | May 17, 2021 | $-0.32 | $-0.46 | -43.8% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about VINC
What is VINC's current stock price?
Vincerx Pharma, Inc. (VINC) is currently trading at $0.01 per share. The stock has moved +0.00% today.
What is the analyst price target for VINC?
The average analyst price target for VINC is $3.00, based on 1 analyst.
What sector is Vincerx Pharma, Inc. in?
Vincerx Pharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VINC's market cap?
Vincerx Pharma, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does VINC pay dividends?
No, Vincerx Pharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACON
Aclarion, Inc.
$6.20
Mkt Cap: $0.0B
DRMA
Dermata Therapeutics, Inc.
$2.14
Mkt Cap: $0.0B
FOXO
FOXO Technologies Inc.
$0.00
Mkt Cap: $0.0B
PIII
P3 Health Partners Inc.
$4.12
Mkt Cap: $0.0B
PPBT
Purple Biotech Ltd.
$0.71
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SLXNW
Silexion Therapeutics Ltd.
$0.03
Mkt Cap: $0.0B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
SYRS
Syros Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
VRPX
Virpax Pharmaceuticals, Inc.
$0.02
Mkt Cap: $0.0B
Explore stocks similar to VINC for comparison